Please use this identifier to cite or link to this item: https://dora.health.qld.gov.au/qldresearchjspui/handle/1/6438
Title: The seroprevalence of SARS-CoV-2-specific antibodies in Australian children: a cross sectional study
Authors: Koirala, Archana
McRae, Jocelynne
Britton, Philip
Downes, Marnie
Prasad, Shayal
Nicholson, Suellen
Winkler, Noni
O’Sullivan, Matthew
Gondalwala, Fatima
Castellano, Cecile
Carey, Emma
Hendry, Alexandra
Crawford, Nigel
Wadia, Ushma
Richmond, Peter
Marshall, Helen
Clark, Julia 
Francis, Joshua
Carr, Jeremy
Bartlett, Adam
McMullan, Brendan
Skowno, Justin
Hannah, Donald
Davidson, Andrew
von Ungern-Sternberg, Britta
Lee-Archer, Paul 
Burgoyne, Laura
Waugh, Edith
Carlin, John
Naing, Zin
Kerly, Nicole
McMinn, Alissa
Hunter, Guillian
Heath, Christine
D’Angelo, Natascha
Finucane, Carolyn
Francis, Laura
Dougherty, Sonia 
Rawlinson, William
Karapanagiotidis, Theo
Cain, Natalie
Brizuela, Rianne
Blyth, Christopher
Wood, Nicholas
Macartney, Kristine
Issue Date: 2024
Publisher: medRxiv
Abstract: <h4>Background</h4> Following reduction of public health and social measures concurrent with SARS-CoV-2 Omicron emergence in late 2021 in Australia, COVID-19 case notification rates rose rapidly. As rates of direct viral testing and reporting dropped, true infection rates were most likely to be underestimated. <h4>Objective</h4> To better understand infection rates and immunity in this population, we aimed to estimate SARS-CoV-2 seroprevalence in Australians aged 0-19 years. <h4>Methods</h4> We conducted a national cross sectional serosurvey from June 1, 2022, to August 31, 2022, in children aged 0-19 years undergoing an anesthetic procedure at eight tertiary pediatric hospitals. Parents or guardians of children and adolescents under 18 years provided written consent and participants aged 18-19 years provided their own consent. Participant questionnaires were administered, and blood samples tested using the Roche Elecsys Anti-SARS-CoV-2 total spike and nucleocapsid antibody assays. S and N seroprevalence adjusted for geographic and socioeconomic imbalances in the participant sample compared to the Australian population was estimated using multilevel regression and poststratification within a Bayesian framework. <h4>Results</h4> Blood was collected from 2,046 participants (median age: 6.6 years). Adjusted seroprevalence of spike-antibody was 92.1 % (95% credible interval (CrI) 91.0-93.3%) and nucleocapsid-antibody was 67.0% (95% CrI 64.6-69.3). In unvaccinated children spike and nucleocapsid antibody seroprevalences were 84.2% (95% CrI 81.9-86.5) and 67.1% (95%CrI 64.0-69.8), respectively. Seroprevalence increased with age but was similar across geographic distribution and socioeconomic quintiles. <h4>Conclusion</h4> Most Australian children and adolescents aged 0-19 years, across all jurisdictions were infected with SARS-CoV-2 by August 2022, suggesting rapid and uniform spread across the population in a very short time period. High seropositivity in unvaccinated children informed COVID-19 vaccine recommendations in Australia. <h4>Funding</h4> Australian Government Department of Health and Aged Care.
Type: other
Appears in Sites:Forensic and Scientific Services Publications

Show full item record

Page view(s)

32
checked on Mar 18, 2025

Google ScholarTM

Check


Items in DORA are protected by copyright, with all rights reserved, unless otherwise indicated.